全球定位標記市場－產業規模、佔有率、趨勢、機會和預測，按產品、治療方式、癌症類型、最終用戶、地區和競爭格局分類，2020-2030年預測

2024年全球定位標記市場規模為9,738萬美元，預計2030年將以5.3%的複合年成長率成長至1.3275億美元。定位標記是一種小型可植入物體，用於醫學影像中，為放射治療和外科手術提供精確的參考點，從而實現腫瘤的精準定位並最大限度地減少對健康組織的損傷。全球定位標記市場的主要驅動力是全球癌症發生率的上升、MRI和CBCT等先進影像技術的廣泛應用以及精準放射治療技術的持續進步。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球標記物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品分類（金屬基標記物、聚合物基標記物、其他定位標記）
  • 按檢查方式（CT/CBCT、MRI、超音波、放射治療）
  • 依癌症類型（攝護腺癌、肺癌、乳癌、胃癌、其他癌症）
  • 按最終使用者（醫院和診所、獨立放射治療中心、癌症研究中心）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美標記物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲標記物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區標記物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲標記物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲標記物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球標記物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• CIVCO Radiotherapy
• IZI Medical Products
• Boston Scientific Corporation
• Naslund Medical AB
• Best Medical International, Inc.
• Nanovi A/S
• Carbon Medical Technologies Inc.
• Eckert & Ziegler
• Innovative Oncology Solutions
• Medtronic plc

第16章：策略建議

第17章調查會社について,免責事項

The Global Fiducial Markers Market, valued at USD 97.38 Million in 2024, is projected to experience a CAGR of 5.3% to reach USD 132.75 Million by 2030. Fiducial markers are small, implantable objects utilized in medical imaging to establish precise reference points for guiding radiation therapy and surgical procedures, thereby enabling accurate tumor localization and minimizing collateral damage to healthy tissue. The global market for these markers is primarily propelled by the increasing worldwide incidence of cancer, the expanding adoption of advanced imaging modalities like MRI and CBCT, and continuous technological advancements in precision radiotherapy techniques.

Key Market Drivers

The rising global incidence of cancer significantly propels demand for fiducial markers by expanding the patient population requiring precise radiation therapy. Growing cancer prevalence necessitates accurate tumor localization, particularly in sensitive anatomical regions. Fiducial markers are essential for precision in modern oncology, enhancing therapeutic efficacy and minimizing collateral damage. According to the American Cancer Society, in April 2024, lung cancer was the most frequently diagnosed cancer in 2022, with approximately 2.5 million new cases globally, highlighting a substantial disease burden often necessitating targeted radiation treatment. This prevalence drives continuous demand for accurate therapeutic guidance.

Key Market Challenges

The significant cost associated with fiducial marker implantation procedures presents a considerable impediment to the growth of the Global Fiducial Markers Market. These expenses, encompassing the markers, surgical expertise, specialized equipment, and necessary follow-up imaging for precise placement, restrict widespread adoption. This high expenditure is particularly challenging within healthcare systems facing budget constraints or limited reimbursement policies, directly impacting market penetration and resulting in lower utilization rates despite the acknowledged benefits of improved treatment accuracy and reduced collateral damage.

Key Market Trends

Biodegradable marker development addresses patient comfort and reduces the need for secondary removal procedures, thereby enhancing patient outcomes and potentially reducing healthcare costs. This innovation aligns with the broader medical shift toward sustainable and patient-friendly solutions. The American Medical Association, at its 2023 Interim Meeting, referred Resolution 2-I-23 concerning single-use/disposable medical devices, acknowledging the need to address adverse environmental consequences and balance fiscal expense with patient safety concerns, which reflects the growing recognition of biodegradable material benefits.

Key Market Players

• CIVCO Radiotherapy
• IZI Medical Products
• Boston Scientific Corporation
• Naslund Medical AB
• Best Medical International, Inc.
• Nanovi A/S
• Carbon Medical Technologies Inc.
• Eckert & Ziegler
• Innovative Oncology Solutions
• Medtronic plc

Report Scope:

In this report, the Global Fiducial Markers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fiducial Markers Market, By Product:

• Metal-based Markers
• Polymer-based Markers
• Other Fiducial Markers

Fiducial Markers Market, By Modality:

• CT/CBCT
• MRI
• Ultrasound
• Radiotherapy

Fiducial Markers Market, By Cancer Type:

• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Gastric Cancer
• Other Cancers

Fiducial Markers Market, By End user:

• Hospitals & Clinics
• Independent Radiotherapy Centers
• Cancer Research Centers

Fiducial Markers Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Fiducial Markers Market.

Available Customizations:

Global Fiducial Markers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fiducial Markers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Metal-based Markers, Polymer-based Markers, Other Fiducial Markers)
  • 5.2.2. By Modality (CT/CBCT, MRI, Ultrasound, Radiotherapy)
  • 5.2.3. By Cancer Type (Prostate Cancer, Lung Cancer, Breast Cancer, Gastric Cancer, Other Cancers)
  • 5.2.4. By End user (Hospitals & Clinics, Independent Radiotherapy Centers, Cancer Research Centers)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Fiducial Markers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Modality
  • 6.2.3. By Cancer Type
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Fiducial Markers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Modality
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Fiducial Markers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Modality
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Fiducial Markers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Modality
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By End user

7. Europe Fiducial Markers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Modality
  • 7.2.3. By Cancer Type
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Fiducial Markers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Modality
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By End user
  • 7.3.2. France Fiducial Markers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Modality
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Fiducial Markers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Modality
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Fiducial Markers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Modality
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Fiducial Markers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Modality
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By End user

8. Asia Pacific Fiducial Markers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Modality
  • 8.2.3. By Cancer Type
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Fiducial Markers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Modality
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By End user
  • 8.3.2. India Fiducial Markers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Modality
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Fiducial Markers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Modality
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Fiducial Markers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Modality
      • 8.3.4.2.3. By Cancer Type
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Fiducial Markers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Modality
      • 8.3.5.2.3. By Cancer Type
      • 8.3.5.2.4. By End user

9. Middle East & Africa Fiducial Markers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Modality
  • 9.2.3. By Cancer Type
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Fiducial Markers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Modality
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Fiducial Markers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Modality
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Fiducial Markers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Modality
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By End user

10. South America Fiducial Markers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Modality
  • 10.2.3. By Cancer Type
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Fiducial Markers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Modality
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Fiducial Markers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Modality
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Fiducial Markers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Modality
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Fiducial Markers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. CIVCO Radiotherapy
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. IZI Medical Products
• 15.3. Boston Scientific Corporation
• 15.4. Naslund Medical AB
• 15.5. Best Medical International, Inc.
• 15.6. Nanovi A/S
• 15.7. Carbon Medical Technologies Inc.
• 15.8. Eckert & Ziegler
• 15.9. Innovative Oncology Solutions
• 15.10. Medtronic plc

16. Strategic Recommendations

17. About Us & Disclaimer